Finally, data suggested that anti-PSGL-1 antibodies are potential candidates for the development of an Ab-based approach in ALCL therapy, alone or in combination with anti-CD30 approaches. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.